Alkermes Plc said the company’s long-acting injectable therapy for schizophrenia has helped reduce symptoms and can become an effective option for ensuring patients stay on medication even after being discharged from hospital.
Just because the flagship hospital gets good marks for patient care does not mean results will be equally good in affiliated hospitals in the same network, a new study finds.
Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.
Klick Health’s growing commercialization partner portfolio is proud of the successful exit of Circulation, one of Klick’s first incubation initiatives.
The U.S. Food and Drug Administration approved the first non-radioactive, dual-tracer for sentinel lymph node biopsy.
Edward–Elmhurst Health announced a partnership with Outcome Health to transform the healthcare experience for patients and providers.
A lot can happen in 20 years. When the FDA Modernization Act (FDAMA) was passed in 1997, a mere 217 of its ~40,000 words were allocated to the presentation of healthcare economic information (HCEI). Those 217 words resided within Section 114 of the Act, giving birth to the abstract universe many of us now commonly refer to as FDAMA 114. Fast-forward to January 2017, and the FDA’s release of its Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers – Draft Guidance for Industry and Review Staff. Now 7,000+ words, this document is likely to significantly alter the way pharmaceutical manufacturers engage with the audience who increasingly holds the keys to its commercial success … payers such as health plans, pharmacy benefits managers (PBMs) and hospital systems.
As private practices close and the number of doctors joining rep-restricted hospital-based and integrated delivery networks of healthcare increases, pharma needs to look at the advantages of mobile marketing to “detail” these hospital-based professionals.
Pharma ad agency bands performed in New York City to raise money for the Children’s Hospital at Montefiore (CHAM).
Even experienced pharma marketers who may have years of developing marketing and communication strategies for hospitals and/or vertically integrated systems might not fully understand and appreciate the critical needs and differentiators of inpatient physicians. With the way this increasingly important channel has quickly evolved, driven by healthcare reform and the value-based reimbursement environment, how can they not only keep up but get out ahead of the needs and solutions this market requires? How will they learn what they need to know to position their products for success? The answer is by listening and partnering.